Related Experiment Videos
beta6 integrin is up-regulated in chronic renal allograft dysfunction
Tokihiko Sawada1, Masahiro Abe, Kohtaro Kai
1Second Department of Surgery, Dokkyo University School of Medicine, Mibu, Tochigi, Japan. tsawada@dokkyomed.ac.jp
Clinical Transplantation
|September 4, 2004
Summary
Beta6 integrin and transforming growth factor-beta1 (TGF-beta1) are up-regulated in chronic renal allograft dysfunction (CAD). This suggests beta6 integrin may be a therapeutic target for treating CAD.
Area of Science:
- Nephrology
- Immunology
- Cell Biology
Background:
- Chronic renal allograft dysfunction (CAD) is a significant clinical challenge.
- Transforming growth factor-beta1 (TGF-beta1) plays a role in fibrotic processes.
- Beta6 integrin is essential for TGF-beta1 activation.
Purpose of the Study:
- To investigate the expression of beta6 integrin and TGF-beta1 in CAD.
- To determine if beta6 integrin and TGF-beta1 are up-regulated in CAD.
- To explore beta6 integrin as a potential therapeutic target for CAD.
Main Methods:
- Immunohistochemical evaluation of 103 renal biopsy samples (normal, acute rejection, CAD).
- Assessment of TGF-beta1 and beta6 integrin expression.
- Semiquantitative analysis of protein reactivity.
Main Results:
- No TGF-beta1 or beta6 integrin detected in normal kidneys.
- Both TGF-beta1 and beta6 integrin reactivity observed in distal tubules in acute rejection and CAD.
- Significantly greater reactivity of TGF-beta1 and beta6 integrin in CAD kidneys compared to normal and acute rejection kidneys.
Conclusions:
- Beta6 integrin and TGF-beta1 are up-regulated in chronic renal allograft dysfunction.
- Beta6 integrin may serve as an alternative therapeutic target for CAD treatment.